Haldol Decanoato (Haloperidol Decanoate)

Haloperidol decanoate is indicated for the long‑term management of several psychiatric conditions where oral therapy may be insufficient or adherence is a concern. It is administered by deep intramuscular injection at intervals ranging from two to four weeks, providing sustained plasma concentrations.

• Schizophrenia, including maintenance treatment after stabilization.
• Acute psychotic episodes when rapid control is needed.
• Manic episodes associated with bipolar disorder.
• Situations requiring a depot formulation to improve compliance.
• Adjunctive therapy in patients with treatment‑resistant psychosis.
• Chronic psychotic disorders where oral dosing is problematic.
• Patients transitioning from oral haloperidol to a long‑acting injectable regimen.

Side effects of haloperidol decanoate reflect its dopamine antagonism and may vary in frequency and severity.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Weight gain or changes in appetite.
• Blurred vision or ocular discomfort.
• Increased prolactin levels causing menstrual changes or galactorrhea.
• Fatigue or weakness.
• Insomnia or disturbed sleep patterns.

Serious

• Tardive dyskinesia, a potentially irreversible movement disorder.
• Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability.
• Severe hypotension or cardiac arrhythmias.
• Severe allergic reactions such as angioedema or anaphylaxis.
• Elevated liver enzymes indicating possible hepatic injury.
• Seizures in patients with a history of epilepsy.

When prescribing haloperidol decanoate, clinicians should evaluate patient history and monitor for specific safety concerns.

• Assess cardiovascular status, especially for QT prolongation risk.
• Monitor for extrapyramidal symptoms and tardive dyskinesia during long‑term use.
• Evaluate liver function before initiation and periodically thereafter.
• Use caution in patients with a history of seizures or neuroleptic malignant syndrome.
• Screen for endocrine effects such as hyperprolactinemia, particularly in women of childbearing age.
• Consider dose adjustments in the elderly or those with renal impairment.
• Avoid abrupt discontinuation to reduce risk of withdrawal or relapse.

Haloperidol decanoate may interact with other medications that affect the central nervous system or cardiac conduction, requiring careful review of a patient’s drug regimen.

Avoid

• Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which can increase extrapyramidal risk.
• Co‑administration with drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Combining with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol levels.

Use with caution

• Sedating agents like benzodiazepines or opioids, which may enhance central nervous system depression.
• Anticholinergic medications, which can mask early signs of extrapyramidal symptoms.
• CYP3A4 inducers such as carbamazepine or rifampin, which may reduce therapeutic effect.